论文部分内容阅读
目的:评价盐酸埃克替尼片用于治疗晚期肺腺癌患者的疗效及安全性。方法:选取2013年2月—2014年3月期间肿瘤科收治的ⅢB期或Ⅳ期肺腺癌患者27例,均给予口服埃克替尼治疗,评价患者用药后肺腺癌疾病进展情况或不良反应发生情况。结果:治疗1月后,27例患者客观缓解率(ORR)为51.85%,疾病控制率(DCR)为77.78%;治疗3月后,ORR占48.15%,DCR占66.67%;用药后的主要不良反应症状为皮疹和腹泻,发生皮疹为16例,腹泻为9例;其他少不良反应有皮肤瘙痒2例,ALT升高为4例,恶心、呕吐为3例,头晕为2例。结论:盐酸埃克替尼用于治疗晚期肺腺癌患者疗效较为确切,且安全性好。
Objective: To evaluate the efficacy and safety of imatinib hydrochloride tablets in the treatment of patients with advanced lung adenocarcinoma. Methods: Twenty-seven patients with stage ⅢB or Ⅳ lung adenocarcinoma admitted to Department of Oncology from February 2013 to March 2014 were enrolled in this study. All patients were given imatinib orally to evaluate the progress of lung adenocarcinoma Reaction occurred. Results: After 1 month of treatment, the objective response rate (ORR) was 51.85% and the disease control rate (DCR) was 77.78% in 27 patients. After 3 months of treatment, ORR accounted for 48.15% and DCR accounted for 66.67% The reaction symptoms were rash and diarrhea, rash was 16 cases, diarrhea was 9 cases; other adverse reactions were skin itching in 2 cases, elevated ALT in 4 cases, nausea and vomiting in 3 cases, dizziness in 2 cases. Conclusion: The efficacy of icotinib hydrochloride in patients with advanced lung adenocarcinoma is relatively accurate and safe.